BAJAJ BROKING
Biocon obtains FDA approval for Micafungin injectable drug, strengthening its antifungal medication portfolio. Micafungin is an antifungal medication utilised to treat various fungal and yeast infections. In FY24, Biocon’s consolidated net profit rose to ₹1,022 crore from ₹463 crore in FY23.
Biotechnology firm Biocon Ltd announced on Monday that it has secured approval from the US Food and Drug Administration (US FDA) for its vertically integrated, complex injectable product micafungin, available in 50mg and 100mg vials. The approval enhances Biocon's portfolio of antifungal medications.
Explore: BIOCON LIMITED
Micafungin is an antifungal medication utilised to treat various fungal and yeast infections. This approval underscores Biocon's commitment to providing effective solutions for combating fungal and yeast-related ailments.
Biocon reported a 57% decline in its consolidated net profit to ₹136 crore for the fourth quarter ended March 2024. This decrease was primarily attributed to higher expenses. Total revenue for the quarter saw a marginal increase to ₹3,966 crore compared to ₹3,929 crore in the previous year.
For the fiscal year ended on March 31, 2024, Biocon witnessed a significant improvement in its consolidated net profit, which rose to ₹1,022 crore from ₹463 crore in the previous fiscal year. Total revenue also saw a substantial increase, reaching ₹15,621 crore compared to ₹11,550 crore in the 2022-23 fiscal year.
While the FDA approval for the Micafungin injectable drug highlights Biocon's progress in expanding its product offerings, the decline in net profit reflects the challenges posed by higher expenses. Nonetheless, the company's overall yearly performance demonstrates growth and resilience in the face of economic fluctuations.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Gold Rate Today | 15 January 2025 | Gold Price in India
15 Jan, 2025 | 40 Min. read
Delhi Court Discharges JSW Steel in Corruption Case; HC Clears Monnet Takeover
15 Jan, 2025 | 2 Min. read
IRFC Emerges L1 Bidder to Finance ₹3,167 Crore for Banhardih Coal Block
15 Jan, 2025 | 2 Min. read
Cipla’s Tax Demand Reduced to ₹559.18 Crores After Revision
15 Jan, 2025 | 2 Min. read
Govt Plans 5-6% Hike in Highway Budget for FY26 After FY25 Slump
15 Jan, 2025 | 2 Min. read
Rikhav Securities IPO- Key Objective & Deep Analysis
15 Jan, 2025 | 5 Min. read
Landmark Immigration IPO- Key Objective & Deep Analysis
15 Jan, 2025 | 5 Min. read
HCL Tech expands partnership with Microsoft to transform contact centres
14 Jan, 2025 | 2 Min. read
BEL secures new orders worth Rs 561 crore, boosting FY25 order book
14 Jan, 2025 | 2 Min. read
ITI Ltd secures Rs 64 crore contracts for Wi-Fi and CCTV systems
14 Jan, 2025 | 2 Min. read
JSW Energy secures LoI for 3.6 GW KSK Mahanadi power plant
14 Jan, 2025 | 2 Min. read
Biocon Biologics’ Johor Bahru Facility Receives FDA VAI Classification
13 Jan, 2025 | 2 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading